Neuroendocrine differentiation in prostate cancer

Prostate Cancer: Principles and Practice

Volumn , Issue , 2005, Pages 143-150

  Huang, Jiaoti ^a   Yao, Jorge L ^a   Anthony Di Sant'Agnese P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41549134047     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Santamaria L, Martin R, Martin JJ, et al. Stereologic estimation of the number of neuroendocrine cells in normal human prostate detected by immunohistochemistry. Appl Immunohistochem Mol Morphol 2002;10:275-281.
2. Huang J, di Sant’Agnese PA. Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts SWJ, Dogliotti L (eds):Advances in oncology: the expanding role of octreotide. Bristol, UK:BioScientifica Ltd, 2002, 243-262.
3. Abdul M, Anezinis PE, Logothetis CJ, et al. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.
4. Dizeyi N, Bjartell A, Nilsson E, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59:328-336.
5. Aprikian AG, Han K, Chevalier S, et al. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297-306.
6. Sun B, Halmos G, Schally AV, et al. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
7. Seethalakshmi L, Mitra SP, Dobner PR, et al. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997:31:183-192.
8. Berruti A, Dogliotti L, Mosca A, et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 2001;47:205-211.
9. Dizeyi N, Konrad L, Bjartell A, et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-98.
10. Petit T, Davidson KK, Lawrence RA, et al. Neuropeptide receptor status in human tumor cell lines. Anticancer Drugs 2001;12:133-136.
11. Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001;12(Suppl 2):S27-29.
12. Wu G, Burzon DT, di Sant’Agnese PA, et al. Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:376-381.
13. Evans AL, Humphrey PA, Srigley JR. Large cell neuroendocrine carcinoma of the prostate. Mod Pathol 2004;17(Suppl 1):150A [abstract].
14. Erasmus CE, Verhagen WI, Wauters CA, et al. Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci 2002;29:375-377.
15. Kawai S, Hiroshima K, Tsukamoto Y, et al. Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report. Pathol Int 2003;53:892-896.
16. Tanaka M, Suzuki Y, Takaoka K, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-436.
17. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-3080.
18. Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415-1420.
19. Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol 2004;12:167-170.
20. Abrahamsson PA, Wadstrom LB, Alumets J, et al. Peptide-hormoneand serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
21. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-653.
22. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167-170.
23. Bonkhoff H, Fixemer T, Hunsicker I, et al. Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections. Virchows Arch 1999;434:71-73.
24. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft:association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91-97.
25. Weinstein MH, Partin AW, Veltri RW, et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-687.
26. Bollito E, Berruti A, Bellina M, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12(Suppl 2):S159-164.
27. Bohrer MH, Schmoll J. Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas. Verh Dtsch Ges Pathol 1993;77:107-110.
28. Aprikian AG, Cordon-Cardo C, Fair WR, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994;151:914-919.
29. Noordzij MA, van der Kwast TH, et al. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
30. Abrahamsson PA, Cockett AT, di Sant’Agnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 1998;8:37-42.
31. Segawa N, Mori I, Utsunomiya H, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001;51:452-459.
32. Steineck G, Reuter V, Kelly WK, et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668-674.
33. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589.
34. Ischia R, Hobisch A, Bauer R, et al. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J Urol 2000;163:1161-1164.
35. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-2597.
36. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an “endocrine marker.” Pathol Res Pract 1989;185:373-380.
37. Ahlgren G, Pedersen K, Lundberg S, et al. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42:274-279.
38. Ismail AH, Altaweel W, Chevalier S, et al. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol 2004;11:2146-2150.
39. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-592.
40. Kollermann J, Helpap B. Neuroendocrine differentiation and shortterm neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol 2001;40:313-317.
41. Li GZ, Zeng L, Zhang J, et al. Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma. Zhonghua Zhong Liu Za Zhi 2003;25:493-495.
42. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
43. Isshiki S, Akakura K, Komiya A, et al. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-515.
44. Ahel MZ, Kovacic K, Tarle M. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Anticancer Res 2001;21:1363-1366.
45. Zaky Ahel M, Kovacic K, Kraljic I, et al. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 2001;21:1475-1479.
46. Chuang CK, Wu TL, Tsao KC, et al. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc 2003;102:480-485.
47. Tarle M, Ahel MZ, Kovacic K. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 2002;22:2525-2529.
48. Sciarra A, Monti S, Gentile V, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168-179.
49. Kamiya N, Akakura K, Suzuki H, et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003;44:309-314.
50. Hvamstad T, Jordal A, Hekmat N, et al. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003;44:215-221.
51. Angelsen A, Syversen U, Stridsberg M, et al. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997;31:110-7.
52. Yashi M, Nukui A, Kurokawa S, et al. Elevated serum progastrinreleasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003;56:305-312.
53. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237.
54. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells (prostatic intraepithelial neoplasia). Proc Natl Acad Sci 1998;95:15382-15387.
55. Hu Y, Ippolito JE, Garabedian EM, et al. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002; 277:44462-44474
56. Burchardt T, Burchardt M, Chen MW, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805.
57. Jongsma J, Oomen MH, Noordzij MA, et al. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50:203-215.
58. Masumori N, Tsuchiya K, Tu WH, et al. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 2004;171:439-442.
59. Cox ME, Deeble PD, Lakhani S, et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999;59:3821-3830.
60. Bonkhoff H, Remberger K. et al. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
61. Rumpold H, Heinrich E, Untergasser G, et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002;53:101-108.
62. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003;62:11-20.
63. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-1737.
64. Xie S, Lin HK, Ni J, et al. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate 2004;60:61-67.
65. Sehgal I, Powers S, Huntley B, et al. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 1994;91:4673-4677.
66. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50-57.
67. Foster BA, Evangelou A, Gingrich JR, et al. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 2002;70:624-632.
68. Wilson EM, Oh Y, Hwa V, et al. Interaction of IGF-binding proteinrelated protein 1 with a novel protein, neuroendocrine differentiation factor, results in neuroendocrine differentiation of prostate cancer cells. J Clin Endocrinol Metab 2001;86:4504-4511.
69. Albrecht M, Doroszewicz J, Gillen S, et al. Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate 2004;58:82-94.
70. Shimizu T, Ohta Y, Ozawa H, et al. Papaverine combined with prostaglandin E2 synergistically induces neuron-like morphological changes and decrease of malignancy in human prostatic cancer LNCaP cells. Anticancer Res 2000;20:761-767.
71. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 2004;111:508-513.
72. Palmer J, Hertzog PJ, Hammacher A. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells. Int J Biochem Cell Biol 2004;36:2258-2269.
73. Mariot P, Vanoverberghe K, Lalevee N, et al. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 2002;277:10824-10833.
74. Vanoverberghe K, Vanden Abeele F, Mariot P, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 2004;11:321-330.
75. Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther 2002;1:525-532.
76. Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489-5495.
77. Xiao D, Qu X, Weber HC. GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept 2002;109:141-148.
78. Jongsma J, Oomen MH, Noordzij MA, et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42:34-44.
79. Ritchie CK, Thomas KG, Andrews LR, et al. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997;30:183-187.
80. Festuccia C, Guerra F, D’Ascenzo S, et al. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 1998;75:418-431.
81. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
82. Sehgal I, Thompson TC. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. Cancer Res 1998;58:4288-4291.
83. Nagakawa O, Furuya Y, Fujiuchi Y, et al. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma. Urology 2002;60:527-530.
84. Ishimaru H, Kageyama Y, Hayashi T, et al. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289-296.
85. Segal NH, Cohen RJ, Haffejee Z, et al. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118:616-618.
86. Salido M, Vilches J, Lopez A. Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol Histopathol 2000;15:729-738.
87. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002;53:118-123.
88. Xue Y, Verhofstad A, Lange W, et al. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2:cell kinetic features of neuroendocrine cells in the human prostate. Am J Pathol 1997;151:1759-1765.
89. Xing N, Qian J, Bostwick D, et al. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001;48:7-15.
90. Chevalier S, Defoy I, Lacoste J, et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 2002;189:169-179.
91. Collado B, Gutierrez-Canas I, Rodriguez-Henche N, et al. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 2004;119:69-75.
92. Mazzucchelli R, Montironi R, Santinelli A, et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000;45:72-79.
93. Grobholz R, Boher MH, Siegsmund M, et al. Correlation between neovascularization and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000;196:277-284.
94. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882-1890.
95. Levine L, Lucci JA 3rd, Pazdrak B, et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63:3495-3502.
96. Huss WJ, Lai L, Barrios RJ, et al. Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 2004;61:142-152.
97. Bang YJ, Pirnia F, Fang WG, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91:5330-5334.
98. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001;7:2941-2948.
99. Steiner H, Godoy-Tundidor S, Rogatsch H, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003;162:655-663.